Compares efficacy of oral semaglutide with subcutaneous semaglutide in obesity, indicating potential for treatment adaptations.
Estimated exposure levels and efficacy observed with oral semaglutide 25 mg were similar to those obtained with subcutaneous semaglutide 2.4 mg, supporting application of oral semaglutide 25 mg to treat individuals with overweight/obesity, with/without T2D.
No takes yet. Share an insight, caveat, or question.
Overgaard et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: